Suppr超能文献

单剂量减毒口服霍乱疫苗Peru-15安全性、免疫原性及保护效力的随机对照人体激发试验

Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine.

作者信息

Cohen Mitchell B, Giannella Ralph A, Bean Judy, Taylor David N, Parker Susan, Hoeper Amy, Wowk Stephen, Hawkins Jennifer, Kochi Sims K, Schiff Gilbert, Killeen Kevin P

机构信息

Division of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA.

出版信息

Infect Immun. 2002 Apr;70(4):1965-70. doi: 10.1128/IAI.70.4.1965-1970.2002.

Abstract

Peru-15 is a live attenuated oral vaccine derived from a Vibrio cholerae O1 El Tor Inaba strain by a series of deletions and modifications, including deletion of the entire CT genetic element. Peru-15 is also a stable, motility-defective strain and is unable to recombine with homologous DNA. We wished to determine whether a single oral dose of Peru-15 was safe and immunogenic and whether it would provide significant protection against moderate and severe diarrhea in a randomized, double-blind, placebo-controlled human volunteer cholera challenge model. A total of 59 volunteers were randomly allocated to groups to receive either 2 x 10(8) CFU of reconstituted, lyophilized Peru-15 vaccine diluted in CeraVacx buffer or placebo (CeraVacx buffer alone). Approximately 3 months after vaccination, 36 of these volunteers were challenged with approximately 10(5) CFU of virulent V. cholerae O1 El Tor Inaba strain N16961, prepared from a standardized frozen inoculum. Among vaccinees, 98% showed at least a fourfold increase in vibriocidal antibody titers. After challenge, 5 (42%) of the 12 placebo recipients and none (0%) of the 24 vaccinees had moderate or severe diarrhea (> or = 3,000 g of diarrheal stool) (P = 0.002; protective efficacy, 100%; lower one-sided 95% confidence limit, 75%). A total of 7 (58%) of the 12 placebo recipients and 1 (4%) of the 24 vaccinees had any diarrhea (P < 0.001; protective efficacy, 93%; lower one-sided 95% confidence limit, 62%). The total number of diarrheal stools, weight of diarrheal stools, incidence of fever, and peak stool V. cholerae excretion among vaccinees were all significantly lower than in placebo recipients. Peru-15 is a well-tolerated and immunogenic oral cholera vaccine that affords protective efficacy against life-threatening cholera diarrhea in a human volunteer challenge model. This vaccine may therefore be a safe and effective tool to prevent cholera in travelers and is a strong candidate for further evaluation to prevent cholera in an area where cholera is endemic.

摘要

秘鲁 - 15是一种口服减毒活疫苗,由霍乱弧菌O1埃尔托稻叶菌株经一系列缺失和修饰后获得,包括删除整个CT遗传元件。秘鲁 - 15也是一种稳定的、运动缺陷型菌株,无法与同源DNA重组。我们希望确定单剂量口服秘鲁 - 15是否安全且具有免疫原性,以及在随机、双盲、安慰剂对照的人类志愿者霍乱攻击模型中,它是否能为中度和重度腹泻提供显著保护。总共59名志愿者被随机分组,分别接受用CeraVacx缓冲液稀释的2×10⁸CFU冻干重组秘鲁 - 15疫苗或安慰剂(仅CeraVacx缓冲液)。接种疫苗约3个月后,其中36名志愿者受到约10⁵CFU由标准化冷冻接种物制备的强毒霍乱弧菌O1埃尔托稻叶菌株N16961的攻击。在接种疫苗者中,98%的人杀弧菌抗体滴度至少升高了四倍。攻击后,12名安慰剂接受者中有5人(42%)出现中度或重度腹泻(腹泻粪便≥3000克),而24名接种疫苗者中无人(0%)出现此类情况(P = 0.002;保护效力为100%;单侧95%置信下限为75%)。12名安慰剂接受者中有7人(58%)出现任何腹泻,24名接种疫苗者中有1人(4%)出现腹泻(P < 0.001;保护效力为93%;单侧95%置信下限为62%)。接种疫苗者的腹泻粪便总数、腹泻粪便重量、发热发生率以及粪便中霍乱弧菌排泄峰值均显著低于安慰剂接受者。秘鲁 - 15是一种耐受性良好且具有免疫原性的口服霍乱疫苗,在人类志愿者攻击模型中对危及生命的霍乱腹泻具有保护效力。因此,这种疫苗可能是预防旅行者霍乱的安全有效工具,并且是在霍乱流行地区预防霍乱进一步评估的有力候选疫苗。

相似文献

3
The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
Infect Immun. 2005 May;73(5):3018-24. doi: 10.1128/IAI.73.5.3018-3024.2005.
4
Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
Clin Infect Dis. 2016 Jun 1;62(11):1329-1335. doi: 10.1093/cid/ciw145. Epub 2016 Mar 21.
6
Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1.
J Infect Dis. 1995 Oct;172(4):1126-9. doi: 10.1093/infdis/172.4.1126.
8
Development of a live, oral, attenuated vaccine against El Tor cholera.
J Infect Dis. 1994 Dec;170(6):1518-23. doi: 10.1093/infdis/170.6.1518.

引用本文的文献

1
Symptoms and adverse events in controlled human infection models.
Front Med (Lausanne). 2025 Aug 14;12:1578560. doi: 10.3389/fmed.2025.1578560. eCollection 2025.
2
, classification, pathogenesis, immune response, and trends in vaccine development.
Front Med (Lausanne). 2023 May 5;10:1155751. doi: 10.3389/fmed.2023.1155751. eCollection 2023.
3
Controlled Human Infection Models To Accelerate Vaccine Development.
Clin Microbiol Rev. 2022 Sep 21;35(3):e0000821. doi: 10.1128/cmr.00008-21. Epub 2022 Jul 6.
4
5
Human Challenge Studies for Cholera.
Curr Top Microbiol Immunol. 2024;445:177-188. doi: 10.1007/82_2022_258.
6
The Interface of and the Gut Microbiome.
Gut Microbes. 2021 Jan-Dec;13(1):1937015. doi: 10.1080/19490976.2021.1937015.
7
The Emergency Response Capacity of Plant-Based Biopharmaceutical Manufacturing-What It Is and What It Could Be.
Front Plant Sci. 2020 Oct 20;11:594019. doi: 10.3389/fpls.2020.594019. eCollection 2020.
8
Vaccines against gastroenteritis, current progress and challenges.
Gut Microbes. 2020 Nov 1;11(6):1486-1517. doi: 10.1080/19490976.2020.1770666. Epub 2020 Jun 18.
9
Oral immunization with a probiotic cholera vaccine induces broad protective immunity against Vibrio cholerae colonization and disease in mice.
PLoS Negl Trop Dis. 2019 May 31;13(5):e0007417. doi: 10.1371/journal.pntd.0007417. eCollection 2019 May.
10
A live vaccine rapidly protects against cholera in an infant rabbit model.
Sci Transl Med. 2018 Jun 13;10(445). doi: 10.1126/scitranslmed.aap8423.

本文引用的文献

4
Validation of a volunteer model of cholera with frozen bacteria as the challenge.
Infect Immun. 1998 May;66(5):1968-72. doi: 10.1128/IAI.66.5.1968-1972.1998.
5
Cholera.
Lancet. 1997 Jun 21;349(9068):1825-30. doi: 10.1016/S0140-6736(97)04486-3.
6
Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers.
J Infect Dis. 1997 Jul;176(1):201-5. doi: 10.1086/514025.
7
8
Development of a live, oral, attenuated vaccine against El Tor cholera.
J Infect Dis. 1994 Dec;170(6):1518-23. doi: 10.1093/infdis/170.6.1518.
9
Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1.
J Infect Dis. 1995 Oct;172(4):1126-9. doi: 10.1093/infdis/172.4.1126.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验